HGH Fragment 176-191 Reconstitution Calculator

No. Neither Fragment 176-191 nor its near-identical analog AOD9604 is approved for any indication. AOD9604 entered human development as an oral anti-obesity agent (phase IIa trials were underway by February 2002 ) and was tracked in obesity drug reviews and trial registries through the mid-2000s, but it never received regulatory approval,. Both compounds are now sold as unregulated "research" peptides with no human safety database,.

AOD9604 is hGH residues 177-191 (Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe) with an added N-terminal tyrosine. Fragment 176-191 is the 16-amino-acid C-terminal peptide Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe, i.e., hGH 177-191 with N-terminal tyrosine (AOD9604). Early preclinical work used hGH 177-191 and AOD9604,,; activity localizes to this same C-terminal antilipogenic/lipolytic domain (animal). Supplied "Frag 176-191" products are AOD9604 (community protocol).

In ob/ob mice, 14 days of hGH or AOD9604 both reduced body-weight gain and increased fat oxidation and plasma glycerol (lipolysis) (animal). Unlike intact hGH, AOD9604 does not compete for the hGH receptor, did not induce hyperglycemia or suppress insulin secretion, and did not drive receptor-mediated cell proliferation. Obese Zucker rats treated orally for 19 days showed no adverse effect on insulin sensitivity by euglycemic clamp (animal). AOD9604 also restores suppressed beta3-adrenergic receptor expression in obese mice (animal), matching its design as a lipolytic hGH fragment without diabetogenic effects. Separately, weekly intra-articular AOD9604 (0.25 mg) improved cartilage morphology and lameness in a rabbit osteoarthritis model, best when combined with hyaluronic acid (animal); human musculoskeletal data are absent.

The clinical candidate was developed as an oral drug: oral AOD9604 at 500 mcg/kg/day for 19 days reduced body-weight gain by >50% in obese Zucker rats (animal), and human trials used the oral route,. Injectable Frag 176-191 on the gray market is administered subcutaneously (community protocol). No published human pharmacokinetic data exist for injected 176-191; systemic (intraperitoneal), and oral dosing both work in animals.

No human dose-finding data are published for the injectable,. Community protocols most commonly use 250-500 mcg/day total subcutaneously in 1-2 injections for 8-12 weeks; a split variant uses 150-250 mcg 2-3 times daily for 4-8 weeks (community protocol). Preclinical oral efficacy began at 500 mcg/kg/day in rats.

Typical community cycles run 8-12 weeks (community protocol). Preclinical metabolic effects were measurable after 14 days (mice, continuous infusion ) to 19 days (rats, oral ). Chronic human safety data do not exist; endocrine, glycemic, and mitogenic risks remain unquantified in humans,.

Lyophilized vials are stable long-term at -20°C. In liquid matrices, AOD9604 degraded extensively within one week at 4°C and 22°C, while remaining stable in dried blood matrices throughout the study. Reconstituted peptide should be refrigerated and used within days-to-weeks (community protocol, consistent with solution-stability data ). For travel, keep lyophilized powder cold or frozen; dried-matrix stability data apply to analytical samples, not constituted vials.

Yes. AOD9604 is prohibited by WADA and has been identified in confiscated vials sold online. Urine screening reaches a 50 pg/mL limit of detection, and the metabolite CRSVEGSCG is significantly more stable than the parent compound, extending the detection window. AOD9604 is included in routine doping-control panels for blood and urine,.